TransMedics Group (NASDAQ:TMDX) Coverage Initiated by Analysts at Stifel Nicolaus

Stock analysts at Stifel Nicolaus started coverage on shares of TransMedics Group (NASDAQ:TMDX) in a note issued to investors on Thursday, Marketbeat reports. The brokerage set a “hold” rating and a $115.00 price target on the stock. Stifel Nicolaus’ price objective points to a potential upside of 10.57% from the stock’s previous close.

A number of other research analysts have also recently weighed in on TMDX. Wall Street Zen cut shares of TransMedics Group from a “buy” rating to a “hold” rating in a report on Saturday, August 30th. Morgan Stanley lifted their price objective on shares of TransMedics Group from $115.00 to $123.00 and gave the company an “equal weight” rating in a report on Friday, August 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Monday, August 25th. Oppenheimer lifted their price objective on shares of TransMedics Group from $130.00 to $150.00 and gave the company an “outperform” rating in a report on Tuesday, June 17th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, TransMedics Group has a consensus rating of “Moderate Buy” and a consensus price target of $122.11.

TransMedics Group Trading Down 0.0%

Shares of TransMedics Group stock opened at $104.01 on Thursday. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17. The firm has a fifty day moving average price of $118.07 and a 200 day moving average price of $104.09. TransMedics Group has a 1 year low of $55.00 and a 1 year high of $169.29. The stock has a market cap of $3.55 billion, a PE ratio of 53.89 and a beta of 2.18.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The firm had revenue of $157.37 million during the quarter, compared to analysts’ expectations of $146.64 million. During the same quarter last year, the company posted $0.35 earnings per share. The firm’s revenue was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. Equities research analysts predict that TransMedics Group will post 1 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Anil P. Ranganath sold 686 shares of the business’s stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the transaction, the insider directly owned 13,955 shares in the company, valued at approximately $1,950,909. The trade was a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Osaic Holdings Inc. boosted its position in TransMedics Group by 48.5% during the second quarter. Osaic Holdings Inc. now owns 21,116 shares of the company’s stock worth $2,830,000 after acquiring an additional 6,899 shares during the last quarter. Thrivent Financial for Lutherans boosted its position in TransMedics Group by 0.9% during the second quarter. Thrivent Financial for Lutherans now owns 24,879 shares of the company’s stock worth $3,334,000 after acquiring an additional 227 shares during the last quarter. State of Wyoming acquired a new position in TransMedics Group during the second quarter worth about $76,000. Caxton Associates LLP acquired a new position in TransMedics Group during the second quarter worth about $242,000. Finally, Public Sector Pension Investment Board boosted its position in TransMedics Group by 8.3% during the second quarter. Public Sector Pension Investment Board now owns 115,335 shares of the company’s stock worth $15,456,000 after acquiring an additional 8,855 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.